Tissue Regenix Group plc

Official Twitter account for Tissue Regenix Group plc (AIM:TRX)

For all investor enquiries please email [email protected]

[Tissue Regenix Group plc @TRX_plc]

#TRX announces that it has received CE certification under the EU Medical Device Regulation and UKCA certification under the UK Medical Device Regulation for OrthoPure® XT, its biological tendon replacement technology.

https://t.co/wqWRtWnC5Q

[Tissue Regenix Group plc @TRX_plc]

Tissue Regenix announces it has been granted a European patent (EP4114476) by the European Patent Office for the Company's innovative dCELL® technology.

Read the full announcement here:
https://t.co/9ODakwN7nh

#TRX #dCELL

[Tissue Regenix Group plc @TRX_plc]

#TRX are attending and exhibiting at the American Academy of Orthopaedic Surgeons (@AAOS1 ) Annual Meeting this week in San Diego.

The event offers information on the latest clinical, scientific, surgical technology and practice management knowledge and expertise.

#AAOS25

[Tissue Regenix Group plc @TRX_plc]

We are pleased to provide a trading update for the year ended 31 December 2024.

Read the full announcement here:
https://t.co/jxePVKDAGs

#TRX

[Walbrook PR @WalbrookPR]

Tissue Regenix (AIM: #TRX, @TRX_plc) Full year trading update

📈Revenue up 8% to $28.4m
↪️Adj EBITDA profit ahead of expectations
💷Cash of $1.9m supports current organic business growth plan

🔗https://t.co/MLOtvSLN8v

[Walbrook PR @WalbrookPR]

📢Tissue Regenix (#TRX, @TRX_plc) announces that its subsidiary, @CellRight_Tech has amended and extended its long-term, multi-year distribution agreement 🤝 with @Arthrex, a premier innovator of #orthopaedic surgical solutions.

🔗https://t.co/Z0A4Tkg68C

[Proactive @proactive_x]

$TRX Tissue Regenix reports strong first half as it focuses on four growth pillars https://t.co/CFb6IJCatf @Tissue_Regenix #TRX

[Proactive @proactive_x]

Tissue Regenix enjoys strong first half with earnings more than doubling @Tissue_Regenix #AIM #TRX https://t.co/YdjaWHJNSX

[Tissue Regenix Group plc @TRX_plc]

TRX interim results highlights:
📈 Revenues increased by 16% to $16.4m
💵 Adjusted EBITDA profit more than doubled to $1.1m
🌟 PBT of $0.1m & gross profit increased to 53%
💰 Cash position of $3.5m
⬆️ A 29% y-o-y increase in tissue processing
https://t.co/jJCLnJ1mnh

[Tissue Regenix Group plc @TRX_plc]

Tissue Regenix will be hosting an @InvestorMeetCo presentation relating to the Company's interim results on Tuesday 10 September at 4.30pm. Investors can register and pre-submit questions here:

https://t.co/uhG5hFyZgi

[Tissue Regenix Group plc @TRX_plc]

Trading update for the six months ended 30 June 2024.

✅ Group revenues ~$16.4 million, 16% increase & record first half
📈 7th consecutive period of growth
⬆️ Expected growth in adjusted EBITDA for H1 24
💵 Cash sufficient to support expansion plans

https://t.co/NZkRtC2oXl

[Hardman & Co @HardmanandCo]

$TRX Recent interview with our Life Sciences analyst converted into report about sector and the need for more institutional support, otherwise it will be lost to intl markets. Update on 2024 capital increases so far. Also, a focus on @TRX_plc opportunity. https://t.co/hF5vqk2VVV

[Hardman & Co @HardmanandCo]

$TRX Another +ve update from @TRX_plc with 1H'24 sales +16% to $16.4m. 7th consecutive six-month period of strong growth. After turning positive in 2023, leverage effect expected to increase EBITDA. Augurs well for full-year. Undemanding EV/sales of 2.0x. https://t.co/ce4ugMP2Kp

[Tissue Regenix Group plc @TRX_plc]

🗣️ Last week, our CEO Daniel Lee introduced a talk about #OrthoPure XT at @Geistlich lunchtime symposium at @ESSKA in Milan, Italy.

📷 Prof. Stefano Zaffagnini also shared his experiences and short-term results with OrthoPure XT for #ACL reconstruction📷https://t.co/gUqOzDZth2

[Walbrook PR @WalbrookPR]

🎉Delighted see our clients (@Tissue_Regenix, @CreoMedical & @hVIVO_UK) are shortlisted for the European Mediscience Awards 2024.

🏆Winners will be announced at the gala dinner on Thursday 13 June 2024.

🔗Check here to find out more https://t.co/hQBeafYyHu

#shortlist #EMA24

[Tissue Regenix Group plc @TRX_plc]

We are delighted to have been shortlisted for two awards at the European Mediscience Awards 2024! 🎉

CEO, Daniel Lee has been shortlisted for Chief Executive of the Year & TRX has been shortlisted for the #BestCommunicator Award👏

@EuromedEvent #EMA2024

[Tissue Regenix Group plc @TRX_plc]

At the Tissue Regenix AGM held earlier today, all resolutions were duly passed on a show of hands.

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 19 March 2024.

https://t.co/PppwKGNBnt

[Walbrook PR @WalbrookPR]

📝@HardmanandCo research on #TRX: Six consecutive periods of >20% growth!

🗣️“...Further growth in 2024 will deliver a fully profitable, cash-generative, group. Cash will be re-invested to expand capacity even further through Phase 2, starting in 2025.”

🔗https://t.co/9r3kgzffNH

[Proactive @proactive_x]

$TRX Tissue Regenix unveils growth strategy and positive EBITDA milestone https://t.co/if6pkjBGKn @Tissue_Regenix #TRX

[Proactive @proactive_x]

$TRX Tissue Regenix posts record revenues and return to profit https://t.co/0629YACg64 @Tissue_Regenix #TRX